The GREENFUND - we're buying the dip, big time, and here's why., page-40

It's easy not to let go!
If there are posters on this forum who are still not clear on what actually happened (including myself), will there be enough clarification provided at the FDA end of Phase 2 meeting, to satisfy officials what is being stated is without question what did happen? Will the Australian results in conjunction with a new USA supplier with closer scrutiny by BOT, back this up to the point where officials are happy that Phase 3 can proceed???? That's the question for all of us!

On the positive side, the safety profile is tremendous, particularly when you compare it with current treatments!

If we receive approval for Phase 3 , the big negative will be the dilutive affect of additional shares with consideration to the share price at the time. End of Phase 2 meeting is 1st QTR 2020. Lets hope data for Dermatitus and rosacea with positive outcomes before cap raise!